Does vitamin B6 as pyridoxal 5'-phosphate support kynurenine pathway enzymes?

The kynurenine pathway is the primary metabolic route for tryptophan catabolism and de novo NAD+ synthesis. Pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, plays a critical regulatory role in this cascade as an essential cofactor.

Molecular mechanisms of PLP-dependent enzymes

• Cofactor binding: PLP is required by key pathway enzymes, including kynureninase (KYNU) and kynurenine aminotransferases (KATs). It binds covalently as an internal aldimine Schiff base to active-site lysine residues to enable catalysis.
• Enzymatic cleavage: In KYNU, PLP drives retro-Claisen-type Cβ–Cγ bond cleavage of kynurenine and 3-hydroxykynurenine (3-HK). In KATs, it facilitates transamination by acting as an electron sink.

Metabolic shunting and biochemical markers

• Selective enzyme impairment: KYNU has a low affinity and high requirement for PLP, making it highly sensitive to B6 depletion. During insufficiency, KYNU activity is selectively blocked, creating a metabolic bottleneck.
• Xanthurenic acid accumulation: The resulting accumulation of upstream intermediates like 3-HK is shunted away from the primary NAD+ pathway. KATs, which are less sensitive to mild PLP depletion, transaminate the excess 3-HK into xanthurenic acid (XA).
• Clinical biomarker: Following an oral tryptophan load (typically 2 g), individuals with vitamin B6 insufficiency exhibit a pronounced, often greater than 30-fold, increase in urinary XA excretion, serving as a highly sensitive functional diagnostic marker.

Bottom line

• Vitamin B6 insufficiency selectively halts kynureninase activity, diverting tryptophan intermediates into alternative transamination pathways that elevate xanthurenic acid. Measuring post-tryptophan-load urinary xanthurenate is a highly reliable functional indicator of subclinical B6 deficiency.